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Background
In young children with asthma, it is recommended to
use pressurised metered dose inhaler (PMDI) with a
valved holding chamber (VHC). The objective of this
study was to evaluate the performances of a VHC with
inhaled corticosteroids.
Methods
In this study, the VHC called Tipshaler (Protec’som,
France) was evaluated with fluticasone (Flixotide®,
50µg/dose, GSK, France) and beclomethasone (QVAR®,
100µg/dose, MEDICIS, Canada). The method according
to the European Pharmacopoeia used a constant flow
rate (30 L / min) was used. Particle size distribution was
measured using a NGI cascade impactor (Copley Scien-
tific, Nottingham, United Kingdom). The fluticasone
and beclomethasone concentrations were assayed by
spectrophotometry at 236 nm and 239 nm respectively.
Results
In the trachea, the mass of fluticasone was higher with
pMDI alone in comparison with VHC (20 ± 0,6 μg vs 0,9
± 0,3 μg, p <0,05). The fine particle dose of fluticasone
was similar with pMDI alone compared to VHC (26 ± 2
μg vs 24 ± 1 μg). Concerning beclomethasone, in the tra-
chea the mass of drugs was higher with pMDI alone in
comparison with VHC (11,6 ± 0,4 vs 1,2 ± 0,2, p<0.05). In
addition, deposition of fine particles of beclomethasone
was similar with pMDI alone in comparison with VHC
(77 ± 1 µg vs 75 ± 1 µg, p<0.05).
Conclusions
The use of valved holding chamber reduces the deposi-
tion of particles of inhaled corticosteroids in the trachea
and allows efficient lung deposition of drugs.
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